Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Obstet Gynecol. Feb 10, 2016; 5(1): 50-57
Published online Feb 10, 2016. doi: 10.5317/wjog.v5.i1.50
Published online Feb 10, 2016. doi: 10.5317/wjog.v5.i1.50
Implications of multigene testing for hereditary breast cancer in primary care
Meghna S Trivedi, Katherine D Crew, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, United States
Katherine D Crew, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, United States
Katherine D Crew, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, United States
Author contributions: Trivedi MS and Crew KD contributed equally to this work.
Conflict-of-interest statement: There is no conflict of interest associated with any of the authors who contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Katherine D Crew, MD, MS, Assistant Professor of Medicine and Epidemiology, Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington Ave, 10-1072, New York, NY 10032, United States. kd59@cumc.columbia.edu
Telephone: +1-212-3051732 Fax: +1-212-3050178
Received: June 28, 2015
Peer-review started: July 11, 2015
First decision: October 8, 2015
Revised: October 29, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: February 10, 2016
Processing time: 216 Days and 21.1 Hours
Peer-review started: July 11, 2015
First decision: October 8, 2015
Revised: October 29, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: February 10, 2016
Processing time: 216 Days and 21.1 Hours
Core Tip
Core tip: Multigene testing for hereditary breast cancer is readily available and some panels can identify over 100 gene mutations. Risk-reducing strategies are available for women with mutations in high-penetrance genes, whereas strategies for managing women with mutations in low-moderate penetrance genes is less clear. Appropriately identifying women who should undergo genetic counseling for hereditary breast cancer and implementing recommended guidelines in those who are found to be high risk can reduce the incidence and mortality of breast cancer.